Senda Biosciences, Inc., a pioneering biopharmaceutical company based in Cambridge, MA, has announced an impressive funding round, successfully raising $123 million to further advance its innovative approaches in the realm of programmable medicines. Founded by Flagship Pioneering, Senda is uniquely positioned at the crossroads of evolutionary biology and cutting-edge technology, leveraging millions of years of evolution to unlock a new class of therapeutics. By tapping into the wealth of knowledge embedded within nature, Senda has developed a proprietary platform that features the first-ever atlas of nature-derived programmable systems, allowing for unparalleled access to the codes required to engineer human cells. This funding will specifically fuel the development of Senda's groundbreaking SendRNAâ„¢ medicines, which harness the power of natural nanoparticles to deliver potent biomolecules precisely to target cells. The potential applications of these innovative therapeutics are vast, promising breakthroughs in the treatment of a myriad of diseases, including infectious, genetic, autoimmune, and metabolic disorders, as well as various oncology indications. Moreover, the funding will support ongoing research into the transformative capabilities of SendRNAâ„¢ in gene editing and protein-based therapies. With this significant investment, Senda is poised to continue its mission of revolutionizing human health by offering accessible and programmable solutions that stand to enhance traditional methods of medical treatment. The combination of sophisticated science and nature's own strategies positions Senda at the forefront of the biopharmaceutical landscape, ready to contribute significantly to the future of medicine.
Senda Biosciences Raises $123M in Series C Funding to Revolutionize Medicine with Nature-Inspired Innovation
Recently funded · $123.0M Series cBiotechnology
Get the full Senda Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
